New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:05 EDTAGIOAgios Pharmaceuticals announces AG-221 orphan drug designation
Agios Pharmaceuticals announced that the U.S. Food and Drug Administration has granted the company orphan drug designation for AG-221 for treatment of patients with acute myelogenous leukemia. AG-221 is an oral IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH2 mutation.
News For AGIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2016
07:32 EDTAGIOAgios Pharmaceuticals appoints Steve Hoerter as Chief Commercial Officer
Agios Pharmaceuticals announced the appointment of Steve Hoerter to the newly created position of chief commercial officer, effective February 16. Hoerter has more than 20 years of global pharmaceutical and biotechnology experience, most recently having served as executive vice president and chief commercial officer at Clovis Oncology, Inc. as well as previous senior commercial roles at Genentech and Roche.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use